A phase i study of DMS612, a novel bifunctional alkylating agent. - Wikidata - awgldk - TriplyDB

A phase i study of DMS612, a novel bifunctional alkylating agent.

A phase i study of DMS612, a novel bifunctional alkylating agent.

http://www.wikidata.org/entity/Q33419113

about

Characterization of the metabolism of benzaldehyde dimethane sulfonate (NSC 281612, DMS612).Advantages of evaluating γH2AX induction in non-clinical drug development.

P2860

Q35984176-EC016B8B-6EAD-4472-AECD-FC45AD966030 Q54985910-52399BF1-1534-4D60-AD90-43A6D31033DB

P2860

A phase i study of DMS612, a novel bifunctional alkylating agent.

http://www.wikidata.org/entity/Q33419113

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A phase i study of DMS612, a novel bifunctional alkylating agent.

@ast

A phase i study of DMS612, a novel bifunctional alkylating agent.

@en

type

label

A phase i study of DMS612, a novel bifunctional alkylating agent.

@ast

A phase i study of DMS612, a novel bifunctional alkylating agent.

@en

prefLabel

A phase i study of DMS612, a novel bifunctional alkylating agent.

@ast

A phase i study of DMS612, a novel bifunctional alkylating agent.

@en

P1433

Q33419113-E1117F80-AC3C-4113-B907-BAC820205121

P1476

Q33419113-633BB851-404E-4CEB-A725-5BE75D0C8AC6

P2093

Q33419113-12ECA6F2-DB1C-49E2-AC14-BAFD74074B3C

Q33419113-1323B917-57D2-4F4D-A33D-917F744C53A3

Q33419113-1F9005EE-0E94-4B23-B79D-B01450549951

Q33419113-29586AAC-16B6-4C26-B08B-D626A485FD38

Q33419113-35E1C117-EB52-442A-B3DB-E79B372D310B

Q33419113-3754AE6A-01C9-481A-899A-0AC86726B224

Q33419113-377E7697-DDBA-421C-902B-296A5AC06DB5

Q33419113-45A40E08-32A5-4095-9114-6E0A0F427B5B

Q33419113-93DA2C9C-461B-4DCA-AD48-130E55D8C1FA

Q33419113-95217F48-B650-483A-AD1C-E131C4579428

P2860

Q33419113-35B87ABF-6FD8-4B93-9BE0-EFFEEFE0230A

Q33419113-4065F26B-966F-4E28-BD6C-527D4F1A738A

Q33419113-4F09BAB7-FEC9-45E3-B1B1-65E9C6BC0272

Q33419113-58DF7A54-8B48-4772-B890-B3AE20597D51

Q33419113-68F9EAB8-3E08-4E51-B0E8-787530D186C1

Q33419113-7B8ED663-010B-4715-B533-3B7EC049A56F

Q33419113-7BE5C8C1-228D-4122-9A17-F9A901F9DDD2

Q33419113-7F459F14-7146-46E2-81EC-853E3E2234FE

Q33419113-81C093E6-A7AB-4F3C-BBBA-315A6315D595

Q33419113-8964284B-DA72-4D9A-8F04-D668794298C5

P304

Q33419113-4B3672F0-940E-4841-8723-9B95B2F00A99

P31

Q33419113-49E4EF1A-CC16-4D24-9FBD-5F3A33AD6BF6

P356

Q33419113-16A53CF6-D222-4EC7-8062-4D06FD03E642

P407

Q33419113-B43729B4-5C27-469F-92E4-1C6B0968C5FA

P433

Q33419113-F5C50F5F-98E4-46BA-A1CE-8709EB93E6E1

P478

Q33419113-4F12A932-6BD9-43BB-AE6A-3D2F07507C21

P50

Q33419113-0AC7B144-9199-4B8E-A73A-CBC2DE07EA7F

Q33419113-8E1D2133-50F7-4D78-BDF4-7CFAE25F0A90

Q33419113-8FF96DD0-3187-421B-A8B9-F870F58E8D79

Q33419113-9888FEAC-9452-4C25-A849-9F5DBBCC50B4

P577

Q33419113-D28130EA-857D-4E33-B678-0A629A5A9A1A

P698

Q33419113-1E629D35-B08C-42C4-9840-35A1740DADC8

P932

Q33419113-9F254923-E49D-4977-B6AC-2CEA65C1F499

P356

1078-0432.CCR-14-1333

P1433

Clinical Cancer Research

P1476

A phase i study of DMS612, a novel bifunctional alkylating agent.

@en

P2093

Asako J Nakamura

http://www.w3.org/2001/XMLSchema#string

Christine Bryla

http://www.w3.org/2001/XMLSchema#string

Christophe E Redon

http://www.w3.org/2001/XMLSchema#string

David R Kohler

http://www.w3.org/2001/XMLSchema#string

Edward Chu

http://www.w3.org/2001/XMLSchema#string

John J Wright

http://www.w3.org/2001/XMLSchema#string

Julie Eiseman

http://www.w3.org/2001/XMLSchema#string

Richard Piekarz

http://www.w3.org/2001/XMLSchema#string

Robert A Parise

http://www.w3.org/2001/XMLSchema#string

Susan E Bates

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma.

FociCounter: a freely available PC programme for quantitative and qualitative analysis of gamma-H2AX foci.

Formation of active products of benzaldehyde dimethane sulfonate (NSC 281612, DMS612) in human blood and plasma and their activity against renal cell carcinoma lines.

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

Effects of the aldehyde dehydrogenase inhibitor disulfiram on the plasma pharmacokinetics, metabolism, and toxicity of benzaldehyde dimethane sulfonate (NSC281612, DMS612, BEN) in mice.

The potential of exploiting DNA-repair defects for optimizing lung cancer treatment.

Intrinsic chemotherapy resistance to the tubulin-binding antimitotic agents in renal cell carcinoma.

Chemotherapy for advanced renal-cell carcinoma: 1983-1993.

Intrinsic drug resistance in primary and metastatic renal cell carcinoma.

P304

721-729

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-14-1333

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Sanjeeve Balasubramaniam

Leonard Appleman

P577

2014-12-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25467180

http://www.w3.org/2001/XMLSchema#string

P932

4755291

http://www.w3.org/2001/XMLSchema#string